Silo Pharma, Inc.
SILO
$0.39
$0.023.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | 960.00% | 640.00% | 327.12% | 1.69% | 1.69% |
| Gross Profit | -87.20% | -58.13% | -29.07% | 0.00% | 0.00% |
| SG&A Expenses | -8.18% | -12.96% | -5.19% | -12.59% | -20.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.78% | -8.90% | 30.31% | 34.61% | 24.69% |
| Operating Income | 2.83% | 9.03% | -30.85% | -35.26% | -25.15% |
| Income Before Tax | -4.77% | 3.76% | -36.69% | -42.08% | -31.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.77% | 3.76% | -36.69% | -42.08% | -31.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.77% | 3.76% | -34.18% | -39.27% | -28.54% |
| EBIT | 2.83% | 9.03% | -30.85% | -35.26% | -25.15% |
| EBITDA | -21.98% | -51.43% | -424.87% | -- | -- |
| EPS Basic | 56.29% | 48.85% | 21.57% | 13.11% | 4.77% |
| Normalized Basic EPS | 56.31% | 48.78% | 19.94% | 11.26% | 2.71% |
| EPS Diluted | 56.29% | 48.85% | 21.57% | 13.11% | 4.77% |
| Normalized Diluted EPS | 56.31% | 48.78% | 19.94% | 11.26% | 2.71% |
| Average Basic Shares Outstanding | 161.49% | 127.54% | 84.84% | 61.51% | 33.74% |
| Average Diluted Shares Outstanding | 161.49% | 127.54% | 84.84% | 61.51% | 33.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |